Targeting chronic COVID-19 lung injury; Tofacitinib can be used against tissue-resident memory T cells.
Biomed Pharmacother
; 147: 112614, 2022 Mar.
Article
in English
| MEDLINE | ID: covidwho-1682939
ABSTRACT
Post-Covid pulmonary fibrosis is evident following severe COVID-19. There is an urgent need to identify the cellular and pathophysiological characteristics of chronic lung squeals of Covid-19 for the development of future preventive and/or therapeutic interventions. Tissue-resident memory T (TRM) cells can mediate local immune protection against infections and cancer. Less beneficially, lung TRM cells cause chronic airway inflammation and fibrosis by stimulating pathologic inflammation. The effects of Janus kinase (JAK), an inducer pathway of cytokine storm, inhibition on acute Covid-19 cases have been previously evaluated. Here, we propose that Tofacitinib by targeting the CD8+ TRM cells could be a potential candidate for the treatment of chronic lung diseases induced by acute SARS-CoV-2 infection.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Piperidines
/
Pyrimidines
/
T-Lymphocyte Subsets
/
CD8-Positive T-Lymphocytes
/
Lung Injury
/
Janus Kinase Inhibitors
/
COVID-19 Drug Treatment
Type of study:
Experimental Studies
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Biomed Pharmacother
Year:
2022
Document Type:
Article
Affiliation country:
J.biopha.2022.112614
Similar
MEDLINE
...
LILACS
LIS